Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · SPRUCE BIOSCIENCES, INC. (SPRB)

Spruce Biosciences Q1 net loss narrows to $12.3 million from $14.0 million

Positive Impact 3 of 5 earnings Written later

Spruce Biosciences reported a first-quarter 2026 net loss of $12.3 million, or $(8.94) per share, down from $14.0 million, or $(23.95) per share, a year earlier, as operating expenses fell to $12.0 million from $14.5 million. The company closed a $69.0 million gross underwritten public offering on April 22, 2026, which included 1,150,000 shares, pre-funded warrants and 180,000 option shares, and reported preliminary, unaudited cash of $107.3 million as of April 30, 2026. Shareholders should note that the offering increases the share count, and the company's stated timeline for a BLA submission for TA-ERT is the fourth quarter of 2026.

Key points

  • Net loss of $12.3 million, or $(8.94) per share, for the quarter ended March 31, 2026, versus $14.0 million, or $(23.95) per share, a year earlier.
  • Total operating expenses of $12.0 million versus $14.5 million; R&D included $5.7 million in one-time product acquisition costs related to SPR202.
  • Cash and cash equivalents of $54.1 million at March 31, 2026, up from $48.9 million at December 31, 2025.
  • Closed $69.0 million in aggregate gross offering proceeds on April 22, 2026; preliminary, unaudited cash of $107.3 million as of April 30, 2026.

The filing

CompanySPRUCE BIOSCIENCES, INC. (SPRB)
Form8-K, current report
Filed with the SECMay 13, 2026, 8:05 AM ET
Accession number0001193125-26-220648

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.